We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Nymox Pharmaceutical new updated Safety Committee review of safety data for its ongoing multi-center U.S. Phase 2 trial of NX-1207 has revealed no serious drug side effects.
Warner Chilcott Company, Inc. announced today that it has received a Paragraph IV Certification Notice from Watson Laboratories, Inc. advising of the filing of an Abbreviated New Drug Application (ANDA) for a generic version of LOESTRIN(R) 24 FE.
Discovery Laboratories Inc. said Tuesday it is making progress on its ongoing investigation into, and remediation efforts for, a problem that has delayed the approval of its lead new drug candidate Surfaxin.
EKR Therapeutics, Inc., an emerging specialty pharmaceutical company, has completed its first institutional financing led by NewSpring Capital and ESP Equity Partners.
The Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based discovery services company, signed a research agreement to identify and develop compounds for two innovative immuno-oncology targets.
Ophthalmic International, the wholly owned subsidiary of Coronado Industries announced today that the company had signed an agreement with O'IA-DA International Inc., to distribute its Pneumatic Trabeculoplasty (PNT) device in Ghana.
The FDA has granted final approval to Teva harmaceutical's abbreviated new drug application (ANDA) to market its generic version of Merck's Proscar (finasteride) tablets in dosages of 5 mg.
Northfield Laboratories have agreed to purchase a building that will house its first commercial facility for producing PolyHeme, the company's human hemoglobin-based oxygen carrier.
The Supreme Court has rejected the FTC's appeal to hear a case that could have ended the practice of reverse payments, spurring swift congressional action to outlaw such agreements.